Resources
82 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 11/19/2019 (updated 3/25/2024)
The intersection of opioid abuse, particularly injection drug use (IDU), and HIV is well documented; in fact, IDU is the second most frequent route of HIV transmission. Injection drug use, either directly or via sexual contact with an IDU partner, accounts for one-third of the estimated AIDS cases since the beginning of the epidemic, and 18 percent of new infections in the United States.
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 11/19/2019 (updated 3/25/2024)
The document provides guidance on how to plan for an outbreak of HIV or HCV among PWID including considerations for developing an outbreak response plan to minimize the impact of the outbreak on the community and stop further transmission. The document also outlines strategies to detect and investigate a possible outbreak.
Posted 7/28/2023 (updated 3/26/2024)
The Rural Health Information Hub's (RHIhub) article covers best practices and emerging models for rural harm reduction programs. Among those featured in the article is the RCORP-TA grantee, the South Dakota State University's program Stigma, Treatment, Avoidance and Recovery in Time - South Dakota (START-SD).
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 8/25/2023 (updated 3/26/2024)
As HIV transmission via injection drugs are increasing, knowing the variation in which the the transmission occurs can be beneficial in treatment and intervention. Authors of the study look into the frequency and distribution of HIV transmission behaviors among people who use drugs in rural areas to possibly determine if interventions could be universally effective. Data collected in the study suggests that there are many variations in the transmission behaviors.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 3/22/2022 (updated 3/27/2024)
Infective endocarditis is a life-threatening inflammation of the heart’s chambers and valves that can be difficult and expensive to treat. Like hepatitis and HIV, infective endocarditis can be caused by using needles that are not sterile. This infographic highlights basic information about infective endocarditis alongside an anatomical image of a human heart.